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S U M M A R Y
Objective: To examine the association between trimethoprim/sulfamethoxazole, other US Food and Drug
Administration (FDA) C and D anti-infectives, and non anti-infective FDA C, D, and X drugs used during
pregnancy with preterm birth and low birth weight.
Methods: We carried out a retrospective cohort study based on a 50% random sample of women who
gave birth in the Canadian province of Saskatchewan from 1997 to 2000. The association between
trimethoprim/sulfamethoxazole, other FDA C and D anti-infectives (ﬂuconazole, clarithromycin,
doxycycline, and tetracycline), and non anti-infective FDA C, D, and X drugs used during pregnancy
with preterm birth and low birth weight was evaluated using multiple logistic regression, with adjusted
odds ratios (aORs) and 95% conﬁdence intervals (CIs) as association measures.
Results: A total of 17 939 women were included in the ﬁnal analysis. Trimethoprim/sulfamethoxazole
was associated with signiﬁcantly increased risks for preterm birth (aOR 1.51, 95% CI 1.10, 2.08) and low
birth weight (aOR 1.67, 95% CI 1.14, 2.46). Exposure to non anti-infective FDA category C, D and X drugs
was also associated with increased risks for preterm birth (aOR 1.17, 95% CI 1.09, 1.31) and low birth
weight (aOR 1.14, 95% CI 0.92, 1.42), but to a lesser degree. Other FDA C and D anti-infectives were not
(statistically) signiﬁcantly associated with increased risks for preterm birth (aOR 0.93, 95% CI 0.49, 1.77)
or low birth weight (aOR 0.65, 95% CI 0.27, 1.60).
Conclusions: Among FDA C, D and X drugs, trimethoprim/sulfamethoxazole, a folic acid antagonist, has
the strongest association with preterm birth and low birth weight.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Anti-infectives have often been used in pregnancy to treat
various infections.1,2 Some of these anti-infectives are category C
or D drugs according to theUS Food andDrug Administration (FDA)
classiﬁcation system– a systemdeveloped to rate the potential risk
to the fetus of drugs. The FDA system classiﬁes a drug into one of
ﬁve major categories: A, B, C, D and X.3,4 Most drugs are classiﬁed
into category C; these should be given only if potential beneﬁts
outweigh potential risks to the fetus. Categories D and X indicate
evidence of risk in pregnancy.* Corresponding author. Tel.: +1 613 737 8899x73912; fax: +1 613 739 6266.
E-mail address: swwen@ohri.ca (S.W. Wen).
1201-9712/$36.00 – see front matter  2011 International Society for Infectious Disea
doi:10.1016/j.ijid.2011.01.007Trimethoprim/sulfamethoxazole is an effective anti-infective
in the treatment of a variety of infections, and is used as ﬁrst-line
therapy for the treatment of acute and uncomplicated urinary
tract infections in women.5,6 Trimethoprim/sulfamethoxazole is
an FDA category C drug and the most frequently prescribed folic
acid antagonist during pregnancy.7 Folic acid antagonists include
a broad spectrum of drugs with various clinical indications
ranging from epilepsy to mood disorders to urinary tract
infections. One of the common mechanisms of folic acid
antagonists is to deplete folate and to impair folate metabolism.8
Maternal exposure to folic acid antagonists, including trimetho-
prim/sulfamethoxazole, has been found to be associated with
increased risks of various adverse pregnancy outcomes, such as
birth defects, preeclampsia, placental abruption, fetal growth
restriction, and fetal death.7,9,10ses. Published by Elsevier Ltd. All rights reserved.
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ﬂuconazole and clarithromycin (FDA category C drugs) and
doxycycline and tetracycline (FDA category D drugs) are also used
to treat infections, including urinary tract infections.11–15 One
major difference of these anti-infectives when compared to
trimethoprim/sulfamethoxazole is that they do not have the effect
of depleting folate and impairing folate metabolism, although they
may have fetal toxic effects through other mechanisms.16–19 Many
studies have examined the associations of various anti-infectives,
including ﬂuconazole,20,21 doxycycline, tetracycline and clarithro-
mycin,18,22,23 and other anti-infectives24–28 with adverse preg-
nancy outcomes, including birth defects, preterm birth, and low
birth weight, with inconsistent ﬁndings. However, no study has
compared the effects of trimethoprim/sulfamethoxazole and other
anti-infectives on adverse pregnancy outcomes in the same
population. The objective of this study was to examine the
associations of pregnancy use of trimethoprim/sulfamethoxazole
and other FDA C and D anti-infectives with preterm birth and low
birth weight, the two most frequently studied adverse pregnancy
outcomes.
2. Materials and methods
2.1. Study population
This study was based on the linkedmaternal–infant database of
the Canadian province of Saskatchewan. Details of the dataset have
been described elsewhere.29
All live births and stillbirths in Saskatchewan to Saskatchewan
residents that occurred between January 1, 1997 andDecember 31,
2000 were identiﬁed. The database includes prescription informa-
tion for most residents (>90%) of the province of Saskatchewan.
According to Saskatchewan provincial regulations, Saskatchewan
Health cannot release the health care information of an entire
segment of the population (e.g., all pregnant women during a
deﬁned period of time), even if all personal identiﬁers are removed.
To respect the provincial regulations and to maximize the study
power, a random sample (by mother’s provincial health care
number) of approximately 50% of the eligible women during the
period of interest was selected. Infants born to mothers of
registered Indians had to be excluded from the study because
drug information is not available for them; women with less than
one year of health coverage were also excluded from this study.
Subjects with multiple birth pregnancies (twins and triplets or
higher order multiples) were excluded because of concerns for the
correlated outcomes and also potentially major confounding from
multiple pregnancy (multiple birth pregnancy has signiﬁcantly
higher rates of preterm birth and low birth weight), which may be
difﬁcult to adjust for by regression analysis alone.
2.2. Ascertainment of pregnancy drug exposure
Ascertainment of FDA category C, D, and X drug use during
pregnancy was determined using information in the outpatient
prescription drug database. Each mother was assigned an index
date equal to the date of delivery. Pregnant women with at least
one prescription formedications dispensed during pregnancywere
considered as exposed. The pregnancy period of drug exposurewas
calculated based on the combination of gestational age, date of
delivery, and drug dispensing dates. Information on maternal and
neonatal characteristics, such as age, parity (based on numbers of
live births and stillbirths), and social assistance plan status were
obtained from the provincial population registry and birth
registration ﬁles. Chronic disease status was based on a chronic
disease score calculated using outpatient prescription drug data in
the year prior to the index date, following previously establishedmethods.30 These variables were considered as confounding
variables affecting the association between FDA category C, D,
and X drugs during pregnancy and adverse pregnancy outcomes.
2.3. Statistical analysis
Preterm birth and low birth weight were the study outcomes.
Preterm birth was deﬁned as a gestational age of <37 completed
weeks, and low birth weight was deﬁned as a birth weight of
<2500 g. Pregnant womenwith at least one FDA category C, D, or X
drug dispensed during pregnancywere considered as exposed. The
study subjects were divided into four groups according to their
pregnancy exposure to FDA category C, D, and X drugs:
trimethoprim/sulfamethoxazole (exposed I), other FDA C and D
anti-infectives (ﬂuconazole, clarithromycin, doxycycline, and
tetracycline; exposed II), non anti-infective FDA C, D, and X drugs
(exposed III), and no exposure to any FDA C, D, or X drugs (non-
exposed). Because of the privacy issues precluding identiﬁcation of
multiple pregnancies, the analyses did not account for women
having had more than one pregnancy during the study period.
The baseline characteristics of the four study groups were
compared. Adjusted odds ratios (aORs) and 95% conﬁdence
intervals (CIs) associated with the different exposure groups (no
exposure as the reference) were estimated. The aOR was obtained
through the use of a multiple logistic regression model with
adjustment for year of birth, maternal age, parity, chronic disease
score, and Saskatchewan Assistance Plan coverage (an indictor of
poverty). Finally, the proportions of women who used trimetho-
prim/sulfamethoxazole and other FDA category C and D anti-
infectives during pregnancy were examined. All analyses were
performed using SAS v. 9.1.3 (SAS Institute Inc., Cary, NC, USA).
3. Results
A total of 17 949 eligible pregnant women were identiﬁed from
the database. Ten women were excluded because they were
exposed to both trimethoprim/sulfamethoxazole and at least one
other FDA C or D anti-infective, leaving 17 939 women for the ﬁnal
analysis.
Maternal characteristics in the four study groups are shown in
Table 1. Women exposed to FDA C, D, or X drugs (including those
exposed to trimethoprim/sulfamethoxazole or other FDA C and D
anti-infectives) tended to be younger, to have a chronic disease,
and to be on the Saskatchewan Assistance Plan.
Tables 2 and 3 present aORs and 95% CIs for preterm birth and
low birth weight, respectively, associated with the different drug
exposures. After adjustment for year of birth, maternal age, parity,
chronic disease score, and Saskatchewan Assistance Plan coverage,
exposure to trimethoprim/sulfamethoxazole was associated with
signiﬁcantly increased risks for pretermbirth and lowbirthweight.
The differences in event rates between the exposed vs. unexposed
groups were substantial (34/447 vs. 715/14 537 in the case of
preterm birth, and 30/447 vs. 509/14 537 in the case of low birth
weight) and very little of these differences appears to be explained
by the confounders entered into the model (crude OR 1.59 vs. aOR
1.51 for preterm birth and crude OR 1.98 vs. aOR 1.67 for low birth
weight). Exposure to non anti-infective FDA category C, D or X
drugs was also associated with increased risks for preterm birth
and low birth weight. On the other hand, exposure to other FDA C
or D anti-infectives was associated with decreased (statistically
non-signiﬁcant) risks for preterm birth and low birth weight
compared with no pregnancy exposure.
Table 4 presents the proportions of pregnancy uses of
trimethoprim/sulfamethoxazole and other FDA C and D anti-
infectives. Trimethoprim/sulfamethoxazole was the most fre-
quently used (2.59%), ﬂuconazole (0.62%) and doxycycline
Table 1
Comparison of baseline characteristics among different study groups, Saskatchewan, 1997–2000.
Characteristics Trimethoprim/ sulfamethoxazole Other FDA C or D anti-infectives Non anti-infective FDA C, D, or X drugs No exposure
No. of subjects 447 188 2767 14 537
Year of delivery
1997 129 (28.86) 36 (19.15) 676 (24.43) 3730 (25.66)
1998 99 (22.15) 43 (22.87) 684 (24.72) 3793 (26.09)
1999 99 (22.15) 47 (25) 696 (25.15) 3612 (24.85)
2000 120 (26.85) 62 (32.98) 711 (25.70) 3402 (23.40)
Maternal age, years
<20 74 (16.55) 24 (12.77) 282 (10.19) 1070 (7.36)
20–29 252 (56.38) 111 (59.04) 1556 (56.23) 8278 (56.94)
30 121 (27.07) 53 (28.19) 929 (33.57) 5189 (35.70)
Parity
1 197 (44.07) 79 (42.02) 1103 (39.86) 5851 (40.25)
2 250 (55.93) 109 (57.98) 1664 (60.14) 8686 (59.75)
Chronic disease score
0 369 (82.55) 150 (79.79) 1743 (62.99) 13 714 (94.34)
1 78 (17.45) 38 (20.21) 1024 (37.01) 823 (5.66)
Saskatchewan Assistance Plan coverage
No 332 (74.27) 148 (78.72) 2238 (80.88) 13 066 (89.88)
Yes 115 (25.73) 40 (21.28) 529 (19.12) 1471 (10.12)
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(0.03%) were the least used. More than half of these drugs were
used during the ﬁrst trimester.
4. Discussion
This population-based study investigated the different effects
of pregnancy exposure to trimethoprim/sulfamethoxazole vs.
other FDA C and D anti-infectives on preterm birth and low birth
weight. Signiﬁcantly increased risks for preterm birth and low
birth weight associated with trimethoprim/sulfamethoxazole
exposure, but decreased risks (statistically not signiﬁcant) with
exposure to other FDA C and D anti-infectives were found.
Exposure to non anti-infective FDA C, D, and X drugs was also
associated with increased risks for preterm birth and low birth
weight. These observations are in general consistent with
reported ﬁndings in the literature.2,7,22,23,28,31,32 However, theTable 2
Odds ratios for preterm birth (<37weeks) in the different drug exposure groups, Sask
Variable Preterm birth/No. pr
Year of delivery
1997 235/4571
1998 243/4619
1999 234/4454
2000 228/4295
Maternal age, years
<20 105/1450
20–29 512/10 197
30 323/6292
Parity
1 474/7230
2 466/10 709
Chronic disease score
0 774/15 976
1 166/1963
Saskatchewan Assistance Plan coverage
No 754/15 784
Yes 186/2155
Drug exposure
No exposure 715/14 537
Trimethoprim/sulfamethoxazole 34/447
Other FDA C or D anti-infectives 10/188
Non anti-infective FDA C, D, or X drugs 181/2767
aOR, adjusted odds ratio; CI, conﬁdence interval.
a The adjusted odds ratio was evaluated through a logistic regression model with
Saskatchewan Assistance Plan coverage.
b Statistically signiﬁcant difference.current study is the ﬁrst to compare the effects of trimethoprim/
sulfamethoxazole exposure vs. other FDA C and D anti-infectives
and non anti-infective FDA C, D, and X drug exposures in the same
population.
Compared with previous studies in the same ﬁeld, the current
study has several strengths. Because this study was based on a 50%
random sample of eligible women from the Canadian province of
Saskatchewan, selection bias has been reduced. The ability to use
the unique health service number hosted by the provincial
Ministry of Health enabled a valid linkage of several databases
(i.e., provincial registration, outpatient prescription drugs, hospital
discharge, physician services, and vital statistics). Drug exposure
information was abstracted from pharmacy databases, which
avoided recall bias. In our study, drug exposure time was
determined by the gestation period at the date of drug dispensing,
allowing the period of exposure during pregnancy to be estimated
quite precisely.atchewan, 1997–2000
egnancies aORa (95% CI) p-Value
(Reference)
1.03 (0.86, 1.24) 0.806
1.04 (0.86, 1.25) 0.819
1.04 (0.86, 1.26) 0.737
(Reference)
1.03 (0.81, 1.30) 0.001b
1.25 (0.96, 1.63) 0.003b
(Reference)
0.63 (0.54, 0.72) 0.000b
(Reference)
1.23 (1.13, 1.35) 0.000b
(Reference)
1.87 (1.55, 2.25)) 0.00b
(Reference)
1.51 (1.10, 2.08) 0.016b
0.93 (0.49, 1.77) 0.811
1.17 (1.09, 1.31) 0.001b
adjustment for year of birth, maternal age, parity, chronic disease score, and
Table 3
Odds ratios for low birth weight (<2500g) in the different drug exposure groups, Saskatchewan, 1997–2000.
Variable Low birth weight/ No. of children aORa (95% CI) p-Value
Year of delivery
1997 179/4571 (Reference)
1998 182/4619 1.02 (0.82, 1.25) 0.997
1999 162/4454 0.94 (0.75, 1.16) 0.392
2000 156/4295 0.93 (0.75, 1.16) 0.435
Maternal age, years
<20 80/1450 (Reference)
20–29 366/10 197 0.98 (0.75, 1.29) 0.001b
30 232/6292 1.20 (0.89, 1.62) 0.003b
Parity
1 348/7230 (Reference)
2 330/10 709 0.61 (0.52, 0.72) 0.000b
Chronic disease score
0 557/15 976 (Reference)
1 121/1963 1.22 (1.10, 1.35) 0.000b
Saskatchewan Assistance Plan coverage
No 543/15 784 (Reference)
Yes 113/2155 1.81 (1.46, 2.25)) 0.000b
Drug exposure
No exposure 509/14 537 (Reference)
Trimethoprim/sulfamethoxazole 30/447 1.67 (1.14, 2.46) 0.001b
Other FDA C or D anti-infectives 5/188 0.65 (0.27, 1.60) 0.545
Non anti-infective FDA C, D, or X drugs 134/2767 1.14 (0.92, 1.42) 0.001b
aOR, adjusted odds ratio; CI, conﬁdence interval.
a The adjusted odds ratio was evaluated through a logistic regression model with adjustment for year of birth, maternal age, parity, chronic disease score, and
Saskatchewan Assistance Plan coverage.
b Statistically signiﬁcant difference.
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results. Since the study relied on existing administrative health
records, certain variables of interest, such as maternal education,
cigarette smoking, environmental factors (air pollution), over-the-Table 4
Proportion of pregnancy uses of FDA C and D anti-infectivesa
Number Proportion
of users
within the
same
trimester
(%)
The rate
exposed to
FDA C or D
anti-infectives
in the whole
population (%)
During whole pregnancy
Trimethoprim/sulfamethoxazole 447 69.25 2.59
Fluconazole 108 16.57 0.62
Doxycycline 62 9.40 0.35
Tetracycline 25 3.88 0.14
Clarithromycin 6 0.90 0.03
First trimester
Trimethoprim/sulfamethoxazole 249 66.58 1.45
Fluconazole 41 10.97 0.24
Doxycycline 60 15.56 0.34
Tetracycline 23 6.12 0.13
Clarithromycin 3 0.77 0.02
Second trimester
Trimethoprim/sulfamethoxazole 120 80.89 0.71
Fluconazole 24 15.92 0.14
Doxycycline 1 0.64 0.01
Tetracycline 3 1.91 0.02
Clarithromycin 1 0.64 0.01
Third trimester
Trimethoprim/sulfamethoxazole 97 69.93 0.56
Fluconazole 38 27.97 0.22
Doxycycline 1 0.70 0.01
Tetracycline 0 0.00 0
Clarithromycin 2 1.40 0.01
a Because some women used more than one FDA C or D drug over the course of
their whole pregnancy, the numbers in this table do not add up.counter drugs (e.g., folic acid tablets), and maternal weight and
weight gain over pregnancy were not available.
Low socioeconomic status and maternal smoking during
pregnancy have been reported frequently as inﬂuential determi-
nants of adverse birth outcomes (such as low birth weight and
preterm birth).33–35 Low levels of some types of ambient air
pollution may be associated with low birth weight and preterm
birth.36,37 Both smoking and exposure to air pollution are associated
with low socioeconomics status; in our analysis, we adjusted for the
impact of socioeconomics status (i.e., provincial assistant plan).
Moreover, the impact of maternal smoking and air pollution on low
birth weight and preterm birth should also be applicable for the
associations with pregnancy exposure to other C and D anti-
infectives and non anti-infective C, D and X drugs. As a result,
confounding by maternal smoking and air pollution may have a
limited effect on the main study ﬁnding: among FDA C, D and X
drugs, trimethoprim/sulfamethoxazole, a folic acid antagonist, has a
stronger association with preterm birth and low birth weight than
otherC andDanti-infectives andnonanti-infective C,D andXdrugs.
Folic acid supplementation and duration of anti-infective
therapy are also important for this study; however these variables
were not available in the database.
Low birth weight was pre-coded by staff at the Saskatchewan
Ministry of Health and was provided to the researchers as a
dichotomized variable. Low birth weight is caused either by
shortened gestation (i.e., preterm birth) or slow intrauterine
growth (i.e., fetal growth restriction), with somewhat different
etiology,38 or a combination of the two. For etiological research, it
is preferable to use a measure of fetal growth (e.g., small-for-
gestational age) than low birth weight.
Although using pharmacy records avoided the potential of
recall errors for drug exposure by participants, the authors cannot
know for certain whether the patients actually took the drugs after
they obtained them from the pharmacy. Since there is no
compliance information in Saskatchewan’s prescription drug ﬁle,
it is difﬁcult to assess the exact physical exposure to these drugs.
Due to the small sample size, we could not perform an analysis by
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pregnancy used trimethoprim/sulfamethoxazole or other C and D
anti-infectives only once during the entire pregnancy. As a result, it
would be difﬁcult for us to ﬁt models where the indicators for drug
exposure are replaced by numbers of prescriptions to assess a
dose–response relationship, and it would not add much useful
information to the paper, but increase the complexity of analysis
and the interpretation of results.
In the research ﬁle of the Saskatchewan Ministry of Health, the
unique identiﬁcation of women was removed for conﬁdentiality
considerations. As a result, we do not know the number of unique
women or how many infants they had over the 4-year study
period. Canada’s total fertility rate was 1.5 children per woman in
2000, and the birth spacing was more than 33 months, hence the
number of infants from the samemother should be small for the 4-
year study period.39,40 For infants born to the same mother, all
study variables changed, because the situation changed over time.
Taking this into consideration, these study subjects were really
‘unique’ study subjects, even if they were the same biological
mother. As a result, analysis without taking into consideration
whether a women had more than one pregnancy during the study
period would not violate the statistical principle.
The data do not contain information on birth defects or
stillbirths in the index pregnancy. Preterm birth and low birth
weight in infants with birth defects and in stillbirths may have a
different pathophysiology or pathogenesis than preterm birth and
low birth weight in normal live births, and it is preferable to
differentiate the etiology of the two subgroups of preterm birth
and low birth weight.
Regardless of the mechanisms, if trimethoprim/sulfamethoxa-
zole causes preterm birth and low birth weight, it bears public
health importance and should be dealt with appropriately. Yet the
most important limitation of studies of this nature is confounding
by indication. For example, maternal urinary tract infections
during pregnancy increase the risk of preterm birth,41 so it is often
difﬁcult to separate the effect of drugs from the underlying
diseases. However, the two groups of FDA C and D anti-infectives
studied here, namely the folic acid antagonist antibiotics
trimethoprim/sulfamethoxazole and the non-folic acid antagonist
anti-infectives ﬂuconazole, clarithromycin, doxycycline, and tet-
racycline, are both used for infections. The different effects of the
two groups of anti-infectives make it difﬁcult to attribute the
observed effects entirely to confounding by indication. Alternative
interpretations have to be explored.
Biological plausibility is an important criterion in the assess-
ment of causation in epidemiology. For trimethoprim/sulfameth-
oxazole use in pregnancy, there is a strong biological rationale to
believe it may cause increased risks of preterm birth and low birth
weight. Trimethoprim/sulfamethoxazole is a folic acid antagonist,
which may affect the health and wellbeing of the mother and their
offspring in several respects. In the embryonic period, the fetus
goes through rapid growth, morphogenesis, and differentiation.
Folic acid, which is essential for the formation of nucleotides and
amino acids,42 is vital to this process. Folic acid deﬁciency has been
associated with birth defects.43,44 More recently, there has been
accumulating evidence that folic acid deﬁciencymay be associated
with an increased risk of placenta-mediated diseases, such as
preeclampsia, placental abruption, fetal growth restriction, and
fetal death.45–48 Folic acid antagonists, by depleting maternal
folate and impairing folate metabolism, may impair the health and
wellbeing of themother and their offspring bymechanisms similar
to folic acid deﬁciency.49–52 On the other hand, non-folic acid
antagonist anti-infectives (ﬂuconazole, clarithromycin, doxycy-
cline, and tetracycline), although with various other potential fetal
risks,53–56 have no similar impact on folate metabolism. Their use
may be needed under some circumstances, because the mother’scondition may deteriorate if she is left untreated, and because the
outcomes in infants born to mothers with untreated maternal
diseases may be worse. The lack of association between pregnancy
use of these anti-infectives with preterm birth and low birth
weight suggests that maternal use of folic acid antagonists may
carry a high risk to the fetus.
Non anti-infective FDA category C, D, and X drugs include a
broad spectrum of drugs with various clinical indications ranging
from epilepsy to depression, asthma, cancer, and birth control,
such as acetazolamide, beclomethasone, amethopterin, norethin-
drone and selective serotonin reuptake inhibitors (SSRIs), with
many of them having clear fetal toxic effects.7 It is therefore
expected that the risks of preterm birth and low birth weight in
infants born to mothers exposed to these drugs will be higher than
in infants born to mothers with no such exposure.
Despite the repeatedly demonstrated adverse effects of the use
in pregnancy of trimethoprim/sulfamethoxazole, it is worrisome to
ﬁnd that trimethoprim/sulfamethoxazole has remained the
dominant prescription anti-infective for pregnant women. Al-
though the use of anti-infectives in pregnancy sometimes cannot
be avoided because theymay be needed to treat maternal diseases,
physicians caring for women of reproductive age, and particularly
pregnant women or those at high risk of unintended pregnancy,
with medical conditions for which anti-infectives are often
prescribed, may need to carefully consider the speciﬁc anti-
infectives for treatment, and the use of trimethoprim/sulfameth-
oxazole should be minimized. For those patients whomust remain
on this medication, there is also the possibility of increasing
supplemental folic acid (i.e. 5 mg po OD). For example, in the study
by Herna´ndez-Dı´az et al. of the association between pregnancy
exposure to folic acid antagonists and birth defects, the use of
multivitamin supplements containing folic acid diminished the
adverse effects of the folic acid antagonist.9 The recent study by
Czeizel et al. shows the strong effect of folic acid supplementation
in the reduction of preterm birth.57 Increased surveillance of the
outcomes of pregnancy among women who require treatment
with trimethoprim/sulfamethoxazole is also needed.
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